Patents by Inventor Rohn Lee Millican
Rohn Lee Millican has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8273854Abstract: The invention provides specific GLP-1 analogs fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, decreased immunogenicity, and reduce effector activity. The fusion proteins are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.Type: GrantFiled: October 31, 2008Date of Patent: September 25, 2012Assignee: Eli Lilly and CompanyInventors: Wolfgang Glaesner, Rohn Lee Millican, Jr., Andrew Mark Vick
-
Patent number: 8183340Abstract: The invention provides GLP-1 compounds coupled to two polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating conditions or disorders benefited by lowering blood glucose, decreasing food intake, decreasing gastric or intestinal emptying, increasing beta (?) cell population, or decreasing gastric or intestinal motility.Type: GrantFiled: May 11, 2006Date of Patent: May 22, 2012Assignee: Eli Lilly and CompanyInventors: Wolfgang Glaesner, John Philip Mayer, Rohn Lee Millican, Jr., Andrew Mark Vick, Lianshan Zhang
-
Publication number: 20110212092Abstract: The present invention relates to glucagon receptor polypeptide antagonists which inhibit the binding of the hormone glucagon to its receptor. More particularly, the present invention relates to high affinity glucagon receptor antibodies or Fab fragments thereof that inhibit binding of glucagon to its receptor and their use in the treatment or prevention of type 2 diabetes (NIDDM) and related disorders in mammalian species.Type: ApplicationFiled: May 16, 2011Publication date: September 1, 2011Applicant: ELI LILLY AND COMPANYInventors: Andrew Ihor KORYTKO, Rohn Lee MILLICAN, JR.
-
Patent number: 7968686Abstract: The present invention relates to glucagon receptor polypeptide antagonists which inhibit the binding of the hormone glucagon to its receptor. More particularly, the present invention relates to high affinity glucagon receptor antibodies or Fab fragments thereof that inhibit binding of glucagon to its receptor and their use in the treatment or prevention of type 2 diabetes (NIDDM) and related disorders in mammalian species.Type: GrantFiled: March 17, 2009Date of Patent: June 28, 2011Assignee: Eli Lilly and CompanyInventors: Andrew Ihor Korytko, Rohn Lee Millican, Jr.
-
Publication number: 20090252727Abstract: The present invention relates to glucagon receptor polypeptide antagonists which inhibit the binding of the hormone glucagon to its receptor. More particularly, the present invention relates to high affinity glucagon receptor antibodies or Fab fragments thereof that inhibit binding of glucagon to its receptor and their use in the treatment or prevention of type 2 diabetes (NIDDM) and related disorders in mammalian species.Type: ApplicationFiled: March 17, 2009Publication date: October 8, 2009Inventors: ANDREW IHOR KORYTKO, JR., ROHN LEE MILLICAN, JR.
-
Publication number: 20090232807Abstract: The invention provides a stable solution formulation comprising a GLP-1-Fc fusion at a pH between about pH 6 and about pH 8.5. analogs fused to specific IgG4-Fc derivatives. These formulations provide unexpected and considerably greater chemical stability than when compared to GLP-1 -Fc fusions at a pH outside the described ranges. The formulations comprising a GLP-1-Fc fusion are useful in treating diabetes, obesity, initable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.Type: ApplicationFiled: December 15, 2005Publication date: September 17, 2009Applicant: Eli Lilly and CompanyInventors: Wolfgang Glaesner, Rohn Lee Millican, JR.
-
Publication number: 20090215981Abstract: The invention provides GLP-1 compounds coupled to two polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating conditions or disorders benefited by lowering blood glucose, decreasing food intake, decreasing gastric or intestinal emptying, increasing beta (?) cell population, or decreasing gastric or intestinal motility.Type: ApplicationFiled: May 11, 2006Publication date: August 27, 2009Inventors: Wolfgang Glaesner, John Philip Mayer, Rohn Lee Millican, JR., Andrew Mark Vick, Lianshan Zhang
-
Patent number: 7576190Abstract: The invention provides specific FGF-21 compounds fused to specific IgG4-Fc or HSA derivatives resulting in fusion proteins that are biologically active with an extended elimination half-life and a slower clearance. These FGF-21 compound fusion proteins and compositions are useful in treating type 2 diabetes, obesity, and metabolic syndrome.Type: GrantFiled: May 2, 2005Date of Patent: August 18, 2009Assignee: Eli Lilly and CompanyInventors: Wolfgang Glaesner, Rohn Lee Millican, Jr., Yu Tian, Sheng-Hung Rainbow Tschang
-
Patent number: 7557183Abstract: The invention provides GLP-1 compounds coupled to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.Type: GrantFiled: March 19, 2004Date of Patent: July 7, 2009Assignee: Eli Lilly and CompanyInventors: Richard Dennis DiMarchi, Wolfgang Glaesner, Rohn Lee Millican, Jr., Andrew Mark Vick, Lianshan Zhang
-
Publication number: 20090074769Abstract: The invention provides specific GLP-1 analogs fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, decreased immunogenicity, and reduce effector activity. The fusion proteins are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.Type: ApplicationFiled: October 31, 2008Publication date: March 19, 2009Inventors: Wolfgang Glaesner, Rohn Lee Millican, JR., Andrew Mark Vick
-
Patent number: 7498308Abstract: Disclosed are glucagon-like peptide-1 (GLP-1) compounds with modifications at one or more of the following positions: 11, 12, 16, 22, 23, 24, 25, 27, 30, 33, 34, 35, 36, or 37. Methods of treating a subject in need of GLP-1 receptor stimulation using these GLP-1 compounds are also disclosed.Type: GrantFiled: May 18, 2006Date of Patent: March 3, 2009Assignee: Eli Lilly and CompanyInventors: Wolfgang Glaesner, Rohn Lee Millican
-
Patent number: 7482321Abstract: The invention encompasses GLP-1 peptides with modifications at various positions coupled with an extended C-terminus that provides increased stability.Type: GrantFiled: January 3, 2003Date of Patent: January 27, 2009Assignee: Eli Lilly and CompanyInventors: Wolfgang Glaesner, Wayne David Kohn, Rohn Lee Millican, Lianshan Zhang
-
Patent number: 7452966Abstract: The invention provides specific GLP-1 analogs fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, decreased immunogenicity, and reduce effector activity. The fusion proteins are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.Type: GrantFiled: June 10, 2004Date of Patent: November 18, 2008Assignee: Eli Lilly and CompanyInventors: Wolfgang Glaesner, Rohn Lee Millican, Jr., Andrew Mark Vick
-
Patent number: 7199217Abstract: The present invention encompasses a GLP-1 analog and compositions and formulations thereof useful for the treatment of hyperglycemia and other various diseases and conditions in mammals.Type: GrantFiled: November 30, 2001Date of Patent: April 3, 2007Assignee: Eli Lilly and CompanyInventors: Richard Dennis DiMarchi, Rohn Lee Millican, Jr., Wolfgang Glaesner
-
Patent number: 7101843Abstract: Disclosed are glucagon-like peptide-1 (GLP-1) compounds with modifications at one or more of the following positions: 7, 8, 12, 16, 18, 19, 20, 22, 25, 27, 30, 33, and 37. Methods of treating a subject in need of GLP-1 receptor stimulation using these GLP-1 compounds are also disclosed.Type: GrantFiled: August 14, 2002Date of Patent: September 5, 2006Assignee: Eli Lilly and CompanyInventors: Wolfgang Glaesner, Rohn Lee Millican, Lianshan Zhang
-
Patent number: 7084243Abstract: Disclosed are glucagon-like peptide-1 (GLP-1) compounds with modifications at one or more of the following positions: 11, 12, 16, 22, 23, 24, 25, 27, 30, 33, 34, 35, 36, or 37. Methods of treating these GLP-1 compounds are also disclosed.Type: GrantFiled: June 1, 2001Date of Patent: August 1, 2006Assignee: Eli Lilly and CompanyInventors: Wolfgang Glaesner, Rohn Lee Millican
-
Publication number: 20040198654Abstract: Disclosed are glucagon-like peptide-1 (GLP-1) compounds with modifications at one or more of the following positions: 7, 8, 12, 16, 18, 19, 20, 22, 25, 27, 30, 33, and 37. Methods of treating a subject in need of GLP-1 receptor stimulation using these GLP-1 compounds are also disclosed.Type: ApplicationFiled: January 29, 2004Publication date: October 7, 2004Inventors: Wolfgang Glaesner, Rohn Lee Millican, Lianshan Zhang
-
Publication number: 20040132647Abstract: The present invention encompasses a GLP-1 analog and compositions and formulations thereof useful for the treatment of hyperglycemia and other various diseases and conditions in mammals.Type: ApplicationFiled: June 10, 2003Publication date: July 8, 2004Inventors: Richard Dennis DiMarchi, Rohn Lee Millican Jr, Wolfgang Glaesner
-
Publication number: 20030220243Abstract: Disclosed are glucagon-like peptide 1 (GLP-1) compounds with modifications at one or more of the following positions: 11, 12, 16, 22, 23, 24, 25, 27, 30, 33, 34, 35, 36, or 37. Methods of treating these GLP-1 compounds are also disclosed.Type: ApplicationFiled: November 19, 2002Publication date: November 27, 2003Inventors: Wolfgang Glaesner, Rohn Lee Millican